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Objectives: Aprotinin is a broad-spectrum serine protease inhibitor that has been
shown to attenuate the systemic inflammatory response in patients undergoing
cardiac surgery with cardiopulmonary bypass. Although -aminocaproic acid is
similar to aprotinin in its ability to inhibit excessive fibrinolysis (ie, plasmin activity
and D-dimer formation), its ability to influence proinflammatory cytokine produc-
tion remains unclear. This study was designed to compare the effects of -amin-
ocaproic acid and aprotinin on plasma levels of interleukin-6 and interleukin-8
during and after cardiopulmonary bypass.
Methods: Sixty patients were randomized in a double-blind fashion to receive
-aminocaproic acid, aprotinin, or saline (placebo) in similar dosing regimens
(loading dose, pump prime, and infusion). Arterial blood samples were collected
before, during, and after cardiopulmonary bypass, and plasma levels of D-dimer,
interleukin-6, and interleukin-8 were measured. Data were analyzed using repeated
measures analysis of variance.
Results: Both -aminocaproic acid and aprotinin administration resulted in signifi-
cant (P .05) reductions in D-dimer and interleukin-8 levels compared with saline.
These reductions in D-dimer and interleukin-8 levels did not differ between the 2
drug-treated groups. The effect of these two antifibrinolytic agents on interleukin-6
was qualitatively similar to that noted with interleukin-8 but did not reach statistical
significance.
Conclusions: When dosed in a similar manner, -aminocaproic acid seems to be as
effective as aprotinin at reducing interleukin-6 and interleukin-8 levels in patients
undergoing primary coronary artery bypass graft surgery. These data indicate that
suppression of excessive plasmin activity or D-dimer formation or both may play an
important role in the generation of proinflammatory cytokines during and after
cardiopulmonary bypass.
Cardiac surgery and cardiopulmonary bypass (CPB) initiate an in-flammatory response characterized by the release of proinflamma-tory cytokines.1-4 Exposure of blood to the foreign surfaces of theCPB circuit, endotoxemia, and ischemia-reperfusion injury all con-tribute to this inflammatory response by activating the complement,coagulation, and fibrinolytic systems.1-5 Interleukin (IL)-6 and IL-8
are two well-known proinflammatory cytokines that are significantly increased
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during and after cardiac surgery with CPB.5-8 IL-6 and IL-8
are soluble proteins secreted by a variety of cell types,
including activated monocytes, tissue macrophages, and
endothelial cells.1,2 Elevations in IL-6 and IL-8 levels after
CPB are associated with an increased risk of organ inju-
ry9-12 and death.13
The full-Hammersmith (high) dose of aprotinin is cur-
rently used in patients undergoing cardiac surgery with CPB
to reduce blood loss and inflammation. This dosing regimen
includes a bolus dose, pump prime, and infusion that is
started before CPB and usually continued until the patient’s
arrival in the intensive care unit. The rationale for using this
high-dose regimen is based on the need to maintain suffi-
cient aprotinin levels to inhibit a variety of serine proteases
(eg, plasmin, kallikrein, and trypsin) known to contribute to
excessive fibrinolysis and the inflammatory response.2
Aprotinin inhibits fibrinolysis by directly binding plasmin,
the cleavage enzyme responsible for D-dimer formation.
Aprotinin has been shown to inhibit not only markers of
fibrinolysis such as D-dimer14 but also a variety of humoral
and cellular markers of inflammation,1,2 as well as specific
inflammatory processes such as the leukocyte extravasa-
tion.15
-Aminocaproic acid is a lysine analog that is also com-
monly used to inhibit excessive fibrinolysis and reduce
blood loss after cardiac surgery with CPB.16,17 -Aminoca-
proic acid is most effective when levels are maintained
above the therapeutic target during the duration of CPB and
in the early post-CPB period.18 Suboptimal dosing of -ami-
nocaproic acid, especially in some bolus-only protocols,
could lead to incomplete inhibition of fibrinolysis and may
explain its variable efficacy when evaluating blood loss
reduction.16-18 In contrast with aprotinin, very little has
been reported about the effects of lysine analogs, such as
-aminocaproic acid, on the inflammatory response. Given
the limited mode of action (plasmin inhibition only) of this
class of antifibrinolytic agents, it seems unlikely that they
would be as effective as aprotinin at suppressing the inflam-
matory response. We performed a prospective, randomized,
double-blind, placebo-controlled trial to test the hypothesis
that the administration of -aminocaproic acid to patients
undergoing cardiac surgery with CPB will be less effective
than aprotinin in reducing circulating levels of IL-6 and
IL-8. In addition, we measured D-dimer levels to determine
if an equivalent therapeutic effect is achieved when these
antifibrinolytic drugs are administered in a similar fashion.
Methods
Patient Selection
After institutional review board approval and written informed
consent, 60 patients scheduled for elective, primary coronary ar-
tery bypass with CPB were enrolled in this study. Patients were
randomly assigned to receive one of the following: (1) full-dose
aprotinin (2  106 kallikrein inactivation unit [KIU] [load], 2 
106 KIU [pump prime], and 5  105 KIU/h [infusion]); (2)
-aminocaproic acid (100 mg/kg [load], 5 g [pump prime], and 30
mg · kg · h [infusion]); or (3) saline (200 mL [load], 200 mL [pump
prime], and 50 mL/h [infusion]) in a double-blinded fashion.
Exclusion criteria were a history of corticosteroid, dipyridamole,
or anticoagulant therapy, documented platelet or coagulation ab-
normalities, or treatment with thrombolytic therapy within 5 days
of surgery. In addition, patients were not included if serum creat-
inine was greater than 2.0 mg/dL, ejection fraction was less than
30%, or there was a history of adverse reaction to aprotinin or
-aminocaproic acid.
Technique of Operation
After induction with etomidate (0.3 mg/kg), fentanyl (5 to 10
mcg/kg), and rocuronium (1 mg/kg), a pulmonary artery catheter
was inserted through the right internal jugular vein. Anesthesia
was maintained with inhaled isoflurane (0.4%-1.0%) and intrave-
nous fentanyl (25-50 mcg/kg). A propofol infusion (25-50 mcg ·
kg · min) was started at the beginning of “rewarming” and con-
tinued into the postoperative period for sedation.
All the procedures were performed by 1 of 3 surgeons using a
standardized technique for coronary revascularization and myocar-
dial protection. CPB was performed using a hollow fiber oxygen-
ator system (Gish, Irvine, Calif) with nonpulsatile flow using a
centrifugal pump (Biomedicus, Eden Prairie, Minn). The CPB
circuit was primed with 1.8 L of lactated Ringer’s solution, 100 cc
of 25% albumin, 44.6 mEq of sodium bicarbonate, and 50 g of
mannitol. Myocardial protection included moderate hypothermia
(28°C-32°C) with antegrade and retrograde sanguineous (4:1,
blood:crystalloid) cardioplegia every 10 to 20 minutes. Perfusion
flow rates were maintained at 2 L · min · m2 during hypothermia
and at 2.5 L · min · m2 during normothermia.
Anticoagulation was achieved with bovine heparin and moni-
tored to achieve initial kaolin activated clotting time levels of 480
seconds. A Hepcon system (Medtronic, Minneapolis, Minn) was
used for heparin and protamine titration. Blood was collected from
the surgical field by pump suctions during full anticoagulation and
returned to the patient intraoperatively. Mediastinal chest drainage
was not reinfused. Packed red blood cells were transfused when
the hemoglobin level decreased less than 6.0 g/dL during CPB and
8.0 g/dL in the early post-CPB period. Platelet concentrates were
transfused if there was evidence of significant microvascular
bleeding and a platelet count of less than 70,000/L.
Interleukin and D-Dimer Measurements
Arterial blood samples were collected at (1) baseline (before
anesthetic induction), (2) 10 minutes after aortic crossclamp re-
moval, (3) 15 minutes after protamine administration (heparin
reversal), (4) 3 hours after separation from CPB, and (5) 18 to 24
hours after CPB. Blood was drawn from an arterial line directly
into a polypropylene syringe and transferred into a 3.2% Na-
citrate–buffered Vacutainer (Becton Dickinson, Franklin Lakes,
NJ). The concentrations of IL-6 and IL-8 in plasma were deter-
mined with a sandwich-type enzyme-linked immunosorbent assay
kit (R&D Systems, Minneapolis, Minn). D-dimer levels were
determined using a turbidimetric immunoassay (Beckman Coulter,
Miami, Fla). All standards and samples were assayed in duplicate.
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Perioperative Variables
The duration of aortic clamping and CPB, and the number and type
of bypass grafts were recorded. Mediastinal chest tube drainage
and blood product administration were recorded for the first 24
hours after surgery. The duration of postoperative mechanical
ventilation and inotropic support were also documented.
Statistical Analysis
The sample size calculation was based on previous data from
Kawamura and colleagues,7 who demonstrated CPB-induced in-
creases in IL-6 and IL-8. For a significance level of .05, we
calculated that a sample size of 18 per group would have 90%
power to detect a 40% treatment effect in either peak IL-6 or IL-8
levels. We further assumed that combined patient dropout or
incomplete data sets could have an occurrence rate of up to 10%
and therefore determined that enrollment of 60 subjects (20 per
group) would be required for this study.
Statistical analysis was performed with SAS statistical software
(SAS Institute, Inc, Cary, NC). Differences in dichotomous vari-
ables between groups were evaluated by the chi-square test, and
differences in continuous variables were analyzed by a 1-way
analysis of variance (ANOVA) for normally distributed data and a
nonparametric 1-way ANOVA when applicable. The behavior
over time of variables measured at multiple time points in each
subject of each of the 3 treatment groups was analyzed by repeat-
ed-measures ANOVA. Cytokine values at a given time point were
compared by a least-squares means test. All values in the figures,
tables, and text are expressed as mean SD, unless otherwise stated.
Results
A total of 60 patients were randomized to receive aprotinin,
-aminocaproic acid, or saline (n  20 for each treatment
group). Patient and surgical demographic data are outlined
in Tables 1 and 2, respectively. There were no significant
differences between the patient and surgical demographic
variables in any of the treatment groups except in 4-hour
and 24-hour mediastinal chest tube drainage. Patients in the
aprotinin and -aminocaproic acid groups had significantly
less mediastinal chest tube drainage compared with the
patients in the saline group (P  .05). There was no signif-
icant difference in blood loss noted between patients in the
aprotinin and -minocaproic acid groups.
D-Dimer Levels
The effect of aprotinin and -aminocaproic acid on periop-
erative D-dimer formation is illustrated in Figure 1. D-dimer
levels in all 3 treatment groups increased significantly (P 
.001) from baseline during CPB (after aortic crossclamp
removal), peaked after protamine administration, and re-
mained significantly elevated 3 hours post-CPB. Both
-aminocaproic acid and aprotinin administration resulted in
a significant (P  .0001) overall treatment effect on D-
dimer levels compared with saline. Furthermore, at each of
the 3 time points, D-dimer levels were significantly (P 
.0001) attenuated by -aminocaproic acid and aprotinin.
There were no differences in the D-dimer levels between
patients who received -aminocaproic acid or aprotinin.
Interleukin Levels
The influence of CPB on IL-6 and IL-8 for each treatment
group (saline, aprotinin, and -aminocaproic acid) is illus-
TABLE 1. Patient demographics
Saline Aprotinin -Aminocaproic acid
No. of patients 20 20 20
General
Age (y) 63 8 64 9 62 9
Male sex - no. (%) 20 (100) 20 (100) 20 (100)
Body mass index 29.5 4.1 29.1 6.1 30.8 4.6
Ejection fraction (%) 44 13 44 11 51 13
Cardiovascular risk factors
Current smoking (3 mo) 3 (15) 4 (20) 4 (20)
Hypertension 18 (90) 16 (80) 18 (90)
Hypercholesterolemia 15 (75) 18 (90) 16 (80)
Diabetes mellitus 10 (50) 6 (30) 11 (55)
Previous cardiac history
Myocardial infarction 12 (60) 7 (35) 10 (50)
Canadian Cardiovascular Society score 3.0 0.7 3.0 0.6 3.0 0.9
New York Heart Association classification 1.8 0.9 1.8 0.8 1.9 1.0
Preoperative medications
Aspirin 20 (100) 20 (100) 20 (100)
Intravenous heparin 3 (15) 2 (10) 5 (25)
Statin therapy 12 (60) 14 (70) 17 (85)
Beta-blockers 18 (90) 17 (85) 16 (80)
Angiotensin-converting enzyme inhibitors 14 (70) 15 (75) 14 (70)
Values are mean  SD unless otherwise indicated. Values in parentheses represent percentages of each group. No values were significantly different
between groups.
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trated in Figures 2 and 3, respectively. There were no
significant differences in preinduction (baseline) levels of
IL-6 and IL-8 among treatment groups. IL-6 and IL-8 levels
increased significantly during CPB (after aortic crossclamp
release) compared with baseline levels and peaked after
CPB (post-protamine) in all 3 treatment groups. Three hours
after CPB, proinflammatory cytokine levels decreased from
post-protamine levels and continued to decrease 18 hours
after CPB, but they remained significantly elevated com-
pared with baseline. The administration of -aminocaproic
TABLE 2. Surgical demographics
Saline Aprotinin -Aminocaproic acid
Procedure
CABG only 20 (100) 20 (100) 20 (100)
Single internal thoracic artery use 19 (95) 19 (95) 19 (95)
No. of bypass grafts 3.2 0.9 3.3 1.0 3.4 0.7
Aortic crossclamp time (min) 76 22 76 27 71 17
CPB time (min) 127 34 128 36 123 28
Mean activated clotting times
10 min after initiation of CPB 721 172 685 228 632 90
45 min after initiation of CPB 714 174 733 166 640 130
During normothermic CPB before separation 655 155 725 196 621 159
Anticoagulation
Total heparin (100 IU) 496 130 474 103 437 103
Total protamine (mg) 335 114 366 118 350 145
Mediastinal chest tube drainage
First 4 h (mL) 220 (155, 309) 134* (83, 231) 171* (94, 239)
24 h (mL) 707 (532, 867) 418* (343, 627) 475* (371, 671)
Transfusions (units)
Packed red blood cells (operating room) 0 (0, 0) 0 (0, 0) 0 (0, 0.5)
Platelets (operating room) 0 (0, 0) 0 (0, 0) 0 (0, 0)
Packed red blood cells (intensive care unit) 2 (0, 2) 0 (0, 2) 0.5 (0, 2)
Platelets (intensive care unit) 0 (0, 0.5) 0 (0, 0.5) 0 (0, 0)
Clinical milestones
Mechanical ventilation (h) 22 (18, 42) 21 (14, 44) 24 (21, 42)
Inotropic support (h) 18 (11, 22) 19 (9, 21) 19 (12, 20)
CABG, Coronary artery bypass graft; CPB, cardiopulmonary bypass. Values are mean  SD unless otherwise indicated. Values for mediastinal chest tube
drainage, transfusions, and clinical milestones are reported as median with 25th and 75th percentile values in parentheses.
*Values were significantly different from the saline group (P  .05).
Figure 1. D-dimer concentrations for saline, aprotinin, and -ami-
nocaproic acid treatment groups measured before induction, after
aortic crossclamp removal, 15 minutes after protamine adminis-
tration, and 3 hours after separation from cardiopulmonary bypass
(CPB). The values are expressed as mean  SEM (*P < .05 for
both -aminocaproic acid and aprotinin compared with saline).
Figure 2. Plasma concentrations of interleukin (IL)-6 for saline,
aprotinin, and -aminocaproic acid treatment groups measured
before induction, after aortic crossclamp removal, 15 minutes
after protamine administration, and 3 hours after separation from
CPB. The values are expressed as mean  SEM.
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acid and aprotinin resulted in lower peak IL-6 levels com-
pared with saline but did not reach statistical significance (P
 .097 and P  .229, respectively). Likewise, the overall
treatment effect of -aminocaproic acid (P  .099) and
aprotinin (P  .263) did not reach statistical significance.
Peak IL-8 levels were significantly reduced by -aminoca-
proic acid (P  .003) and aprotinin (P  .017) treatment.
Furthermore, both -aminocaproic acid and aprotinin ad-
ministration resulted in a significant overall treatment effect
on IL-8 levels compared with saline (P  .004 and P 
.024, respectively). There were no significant differences
between the -aminocaproic acid and aprotinin groups with
respect to IL-6 and IL-8 levels at any time during or after
the surgery.
Discussion
Contrary to our hypothesis, this randomized, placebo-con-
trolled study demonstrated that -aminocaproic acid, admin-
istered as described, significantly reduced IL-8 levels in
patients undergoing primary CABG surgery to an extent
equivalent to that achieved with high-dose aprotinin.
-Aminocaproic acid and aprotinin also had a similar qual-
itative effect on IL-6, yet the reductions were not statisti-
cally significant. Aprotinin’s ability to inhibit a variety of
serine proteases other than plasmin did not seem to provide
any significant advantage in reducing IL-6 and IL-8 during
or after CPB. The fact that these two antifibrinolytic agents
had an equal impact on D-dimer levels may have had a
significant influence on our results. Taken together, our
results indicate that aprotinin’s effect on these two well-
known proinflammatory cytokines may be the result of
inhibition of excessive plasmin activity or D-dimer forma-
tion or both.
The role of excessive plasmin activity in the generation
of proinflammatory cytokines has only recently been ex-
plored. The finding that a lysine analog (-aminocaproic
acid) had similar effects on IL-6 and IL-8 release as apro-
tinin indicates that inhibition of excessive plasmin activity
alone may have a greater importance in promoting the
inflammatory response than has been previously appreci-
ated. Plasmin has been shown to directly activate comple-
ment by cleaving C3 resulting in the production of the
anaphylatoxins C3a and C5a, which are known to induce
leukocyte activation and proinflammatory cytokine re-
lease.2,19,20 In addition, Syrovets and colleagues21 demon-
strated that plasmin can also directly induce proinflamma-
tory cytokine release (IL-1, IL-1, and TNF-) by
monocytes. Clearly, a better understanding of the mecha-
nisms by which excessive plasmin activity contributes to
complement activation and inflammatory cytokines will be
required before the full benefits of lysine analogs will be
appreciated in the setting of cardiac surgery.
The equivalent reduction in D-dimer formation by -ami-
nocaproic acid and aprotinin indicate that these two antifi-
brinolytic agents were equally effective at inhibiting fibri-
nolysis in patients undergoing primary CABG surgery.
Whether this was the result of using similar dosing regimens
(loading dose, pump prime, and infusion) or a relatively
low-risk patient population remains unclear. Our dosing
regimen for -aminocaproic acid was based on early work
by Butterworth and colleagues.18 According to their model,
our dosing regimen would have maintained drug levels well
above the therapeutic target (130 g/mL), particularly dur-
ing the late CPB and early post-CPB period when D-dimer
formation is known to peak.18,22 It is certainly plausible that
suppression of D-dimer formation alone may have contrib-
uted to reduction in these proinflammatory cytokines. In
vitro studies by several investigators suggest that exposure
of D-dimer fragments to monocytes initiates the synthesis
and release of IL-6.23-25 Further study will be required to
determine if reductions in D-dimer formation has a causal
relationship with circulating proinflammatory cytokines in
the setting of cardiac surgery.
The limitations of this study are similar to those associ-
ated with any clinical trial attempting to evaluate a drug
effect under a complex set of pathophysiologic conditions.
Although groups appear relatively well matched, there may
exist other covariates that might influence the inflammatory
response. Furthermore, the inflammatory response involves
a myriad of humoral and cellular components other than
IL-6 and IL-8 that may be as important to patient outcomes.
The size of this study may also be a limitation, especially
with regard to IL-6. A nonsignificant trend toward reduction
of IL-6 levels was seen in both drug-treated groups. The
absence of statistical significance may represent a type 2
error. Similarly, this study is underpowered to identify
Figure 3. Plasma concentrations of IL-8 for saline, aprotinin, and
-aminocaproic acid treatment groups measured before induc-
tion, after aortic crossclamp removal, 15 minutes after protamine
administration, and 3 hours after separation from CPB. The values
are expressed as mean  SEM (*P < .05 compared with both
-aminocaproic acid and aprotinin compared with saline).
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important clinical outcomes related to decreases in these
inflammatory markers or thrombotic events (eg, graft oc-
clusion and stroke) that may be associated with our antifi-
brinolytic dosing regimens.
Conclusion
This study found that -aminocaproic acid is as effective as
aprotinin in reducing CPB-induced increases in IL-6 and
IL-8 in patients undergoing primary CABG surgery. The
use of a similar dosing regimen for aprotinin and -amin-
ocaproic acid during CPB and in the early post-CPB period
may have played a significant role in achieving equivalent
reductions in D-dimer levels with both drugs. These data
support the notion that excessive fibrinolysis contributes to
the inflammatory response in this clinical setting. Future
studies will be needed to more fully characterize the effects
of inhibiting excessive fibrinolysis on the inflammatory
response and clinical outcome.
We appreciate the professional reviews of William E. Johnston,
MD, and Gary Hill, MD, FCCM, in the preparation of this article.
References
1. Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory re-
sponse to cardiac surgery: implications for the anesthesiologist. Anes-
thesiology. 2002;97:215-52.
2. Mojcik CF, Levy JH. Aprotinin and the systemic inflammatory re-
sponse after cardiopulmonary bypass. Ann Thorac Surg. 2001;71:745-
54.
3. Hall RI, Smith MS, Rocker G. The systemic inflammatory response to
cardiopulmonary bypass: pathophysiological, therapeutic, and phar-
macological considerations. Anesth Analg. 1997;85:766-82.
4. Taylor KM. SIRS—the systemic inflammatory response syndrome
after cardiac operations. Ann Thorac Surg. 1996;61:1607-8.
5. Hill GE, Whitten CW, Landers DF. The influence of cardiopulmonary
bypass on cytokines and cell-cell communication. J Cardiothorac
Vasc Anesth. 1997;11:367-75.
6. Steinberg JB, Kapelanski DP, Olson JD, Weiler JM. Cytokine and
complement levels in patients undergoing cardiopulmonary bypass.
J Thorac Cardiovasc Surg. 1993;106:1008-16.
7. Kawamura T, Wakusawa R, Okada K, Inada S. Elevation of cytokines
during open heart surgery with cardiopulmonary bypass: participation
of interleukin 8 and 6 in reperfusion injury. Can J Anaesth. 1993;40:
1016-21.
8. Turkoz A, Cigli A, But K, Sezgin N, Turkoz R, Gulcan O, et al. The
effects of aprotinin and steroids on generation of cytokines during
coronary artery surgery. J Cardiothorac Vasc Anesth. 2001;15:603-10.
9. Wan S, Izzat MB, Lee TW, Wan IY, Tang NL, Yim AP. Avoiding
cardiopulmonary bypass in multivessel CABG reduces cytokine re-
sponse and myocardial injury. Ann Thorac Surg. 1999;68:52-7.
10. Massoudy P, Zahler S, Becker BF, Braun SL, Barankay A, Meisner H.
Evidence for inflammatory responses of the lungs during coronary
artery bypass grafting with cardiopulmonary bypass. Chest. 2001;119:
31-6.
11. Gormley SM, McBride WT, Armstrong MA, Young IS, McClean E,
MacGowan SW, et al. Plasma and urinary cytokine homeostasis and
renal dysfunction during cardiac surgery. Anesthesiology. 2000;93:
1210-6.
12. Nandate K, Vuylsteke A, Crosbie AE, Messahel S, Oduro-Dominah A,
Menon DK. Cerebrovascular cytokine responses during coronary ar-
tery bypass surgery: specific production of interleukin-8 and its atten-
uation by hypothermic cardiopulmonary bypass. Anesth Analg. 1999;
89:823-8.
13. Hauser GJ, Ben-Ari J, Colvin MP, Dalton HJ, Hertzog JH, Bearb M,
et al. Interleukin-6 levels in serum and lung lavage fluid of children
undergoing open heart surgery correlate with postoperative morbidity.
Intensive Care Med. 1998;24:481-6.
14. Ray MJ, Marsh NA. Aprotinin reduces blood loss after cardiopulmo-
nary bypass by direct inhibition of plasmin. Thromb Haemost. 1997;
78:1021-6.
15. Asimakopoulos G, Thompson R, Nourshargh S, Lidington EA, Mason
JC, Ratnatunga CP, et al. An anti-inflammatory property of aprotinin
detected at the level of leukocyte extravasation. J Thorac Cardiovasc
Surg. 2000;120:361-9.
16. Munoz JJ, Birkmeyer NJ, Birkmeyer JD, O’Connor GT, Dacey LJ. Is
epsilon-aminocaproic acid as effective as aprotinin in reducing bleed-
ing with cardiac surgery? a meta-analysis. Circulation. 1999;99:81-9.
17. Levi M, Cromheecke ME, de Jonge E, Prins MH, de Mol BJ, et al.
Pharmacological strategies to decrease excessive blood loss in cardiac
surgery: a meta-analysis of clinically relevant endpoints. Lancet. 1999;
354:1940-7.
18. Butterworth J, James RL, Lin Y, Prielipp RC, Hudspeth AS. Pharma-
cokinetics of epsilon-aminocaproic acid in patients undergoing aorto-
coronary bypass surgery. Anesthesiology. 1999;90:1624-35.
19. Rinder CS, Rinder HM, Johnson K, Smith M, Lee DL, Tracey J, et al.
Role of C3 cleavage in monocyte activation during extracorporeal
circulation. Circulation. 1999;100:553-8.
20. Fitch JC, Rollins S, Matis L, Alford B, Aranki S, Collard CD, et al.
Pharmacology and biological efficacy of a recombinant, humanized,
single-chain antibody C5 complement inhibitor in patients undergoing
coronary artery bypass graft surgery with cardiopulmonary bypass.
Circulation. 1999;100:2499-506.
21. Syrovets T, Jendrach M, Rohwedder A, Schule A, Simmet T. Plasmin-
induced expression of cytokines and tissue factor in human monocytes
involves AP-1 and IKKbeta-mediated NF-kappaB activation. Blood.
2001;97:3941-50.
22. Casati V, Gerli C, Franco A, Della Valle P, Benussi S, Alfieri O, et al.
Activation of coagulation and fibrinolysis during coronary surgery:
on-pump versus off-pump techniques. Anesthesiology.
2001;95:1103-9.
23. Mandl J, Csala M, Lerant I, Banhegyi G, Biro J, Machovich R, et al.
Enhancement of interleukin-6 production by fibrinogen degradation
product D in human peripheral monocytes and perfused murine liver.
Scand J Immunol. 1995;42:175-8.
24. Koj A, Guzdek A, Potempa J, Korzus E, Travis J. Origin of circulating
acute phase cytokines: modified proteins may trigger IL-6 production
by macrophages. Preliminary report. J Physiol Pharmacol. 1994;45:
69-80.
25. Robson SC, Shephard EG, Kirsch RE. Fibrin degradation product
D-dimer induces the synthesis and release of biologically active IL-1
beta, IL-6 and plasminogen activator inhibitors from monocytes in
vitro. Br J Haematol. 1994;86:322-6.
Greilich et al Cardiopulmonary Support and Physiology
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 5 1503
CS
P
